Thought Leadership & Other Media

CATEGORIES

Filter by Type

See all

CONTACT THE MEDIA TEAM

If you are a journalist with questions or an interview or media request, please do not hesitate to contact us.
CONTACT US

Archive

see all

Recent Posts

Webinar: What can plug-and-play offer large-scale AAV manufacturing?

by Matteo Pellegrino Published on 3/16/22 7:34 AM Thought Leadership, Cell & Gene Therapy

Webinar: What can plug-and-play offer large-scale AAV manufacturing?
It's with tremendous excitement that we announce the webinar and live Q&A session that highlights our unique technique for Adeno-Associated viral (AAV) vector manufacturing.

The webinar “ What can plug-and-play offer large-scale AAV manufacturing?” will be held on Tuesday, March 22 nd, 2022, at 9:00 am PDT/5:00 pm CET. It will be led by Margherita Neri, Manager of Upstream Vector Development at AGC Biologics, and Claire Wartel, Director of Quality and Compliance, Polyplus-Transfection. We have partnered with Polyplus to develop our AAV manufacturing platform, and this will be a follow-up discussion to our 2021 webinar reviewing the results of our work.
Learn More

AGC Biologics Solves Capacity Shortages in Cell and Gene Therapy Space

by AGC Biologics Events, Thought Leadership, Cell & Gene Therapy, AAV vector manufacturing

AGC Biologics Solves Capacity Shortages in Cell and Gene Therapy Space
The cell and gene therapy (C&GT) market is experiencing an explosion of growth with record-breaking financing, major clinical milestones, and commercial progress creating seemingly vast opportunities.  An enormous pipeline of treatments in the market has created seemingly endless possibilities. However, this explosive growth results in one issue set to derail the promise of this sector – manufacturing capacity shortages. 
 
Capacity shortages were a key topic of discussion at the Meeting on the Mesa last week, one of the premier annual C&GT events organized by the Alliance for Regenerative Medicine. At the event, we met with many companies looking for an experienced partner that can help bring their transformative treatments through every phase of approvals, and eventually to patients in need. 
 
Creating new manufacturing capacity requires investments, lead time and technical expertise. It also requires finding the right CDMO with a global footprint, large-scale capacities and resources, and technical expertise in developing and bringing treatments to market. 
Learn More

AGC Biologics Offers Virtual Tour of Expanded Milan Cell & Gene Therapy Center During European Biotech Week 2021

by Matteo Pellegrino Events, Cell & Gene Therapy, Virtual Site Tour

Since 2013, European Biotech Week has been a premier event offering exclusive content, meetings and demonstrations that highlight how biotech can improve our quality of life. 
 
This year, we are excited to partner with European Biotech Week 2021 to open the doors of our expanded state-of-the-art Cell and Gene Therapy Center of Excellence and production facility in Milan, Italy. 
As a global CDMO, we are laser-focused on building the industry’s best cell and gene therapy (C&GT) and biologics development and manufacturing services. 
On October 1st at 11:00 am CET, AGC Biologics is hosting a free virtual tour that showcases our end-to-end capabilities and our new Process Development and Quality Control laboratories. 
 
You don’t want to miss it, sign-up today! 
Learn More

Webinar: Large-Scale AAV Manufacturing: The Road from Concept to Ready-to-Use Platform

by Matteo Pellegrino Published on 5/20/21 7:30 AM Thought Leadership, Cell & Gene Therapy

It's with tremendous excitement that we announce the webinar and live Q&A session, titled “Large-Scale AAV Manufacturing: The Road from Concept to Ready-to-Use Platform” will be held Wednesday, May 26th at 8:00 AM PDT / 5:00 pm CEST.  This webinar will be co-presented by Margherita Neri, Upstream Vector Process Development Manager, AGC Biologics, and Claire Wartel, Director of Quality and Compliance, Polyplus-Transfection.
Learn More

On-Demand Webinar: Large-Scale LVV Production: Industry-Leading Process Development to High Quality GMP Vector

by David Self Published on 2/25/21 12:00 PM Thought Leadership, Cell & Gene Therapy

The on-demand webinar and Q&A “Large-Scale LVV Production: From Industry-Leading Process Development to High Quality GMP Vector,” with our own Giuliana Vallanti, Director of Development and Global R&D, Cell and Gene Therapy, and the panel of co-hosts is now available to watch for free.

Learn More

On-Demand Roundtable: Streaming and Optimizing Viral Vector Bioprocess and Analytical Development

by David Self Published on 1/15/21 10:38 AM Thought Leadership, Cell & Gene Therapy

Join AGC Biologics' own Mark Womack, Chief Business Officer and Ramin Baghirzade, Sr. Director and Global Cell and Gene Therapy (C&GT) Business Development, and a panel of co-hosts for an on-demand presentation of the C&GT Expert Roundtable on Streaming and Optimizing Viral Vector Bioprocess and Analytical Development, presented by BioInsights.

Learn More

Video: BIO-Europe 2020 Presentation: AGC Biologics' Capabilities and Introduction to Cell and Gene Therapy

by David Self Events, Thought Leadership, Cell & Gene Therapy

Byron Kneller, VP, Process Development, Seattle and Luca Alberici, General Manager, Milan, present AGC Biologics’ end-to-end CDMO protein expression and cell and gene therapy manufacturing capabilities at BIO-Europe in October, 2020. 

Learn More

Article: Process Development: How to Win the Race in Cell & Gene Therapy

by David Self Published on 10/6/20 11:24 AM Thought Leadership, Cell & Gene Therapy

In this spotlight article, presented by BioInsights, Dr. Ramin Baghirzade, AGC Biologics' Global Head of Business Development for Cell & Gene Therapy, shares his expert insights on the state of the industry, and four inter-connected variables exerting pressure on therapeutics developers to improve their processes earlier in the product’s development.

Learn More
All Posts
Follow Us
Join us on LinkedIn Follow us on Twitter